Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: A French national survey

Archives of Disease in Childhood

Volumn 100, Issue 4, 2015, Pages 394-398

  Leroux, Stéphanie ^a,b,c   Zhao, Wei ^a,b,d,e   Bétrémieux, Pierre ^c   Pladys, Patrick ^c,f   Saliba, Elie ^g   Jacqz Aigrain, Evelyne ^a,b,d  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e SHANDONG UNIVERSITY   (China)

^f UNIVERSITÉ DE RENNES 1   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; CLOXACILLIN; GENTAMICIN; METRONIDAZOLE; NETILMICIN; OXACILLIN; PENICILLIN G; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CONTINUOUS INFUSION; DRUG DOSE REGIMEN; EVIDENCE BASED MEDICINE; FRANCE; HEALTH SURVEY; HUMAN; INDIVIDUALIZATION; LOADING DRUG DOSE; NEWBORN; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FRANCE; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INTENSIVE CARE, NEONATAL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC;

EID: 84924939522     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2014-306873     Document Type: Article

References (46)

1. Marchant EA, Boyce GK, Sadarangani M, et al. Neonatal sepsis due to coagulase-negative staphylococci. Clin Dev Immunol 2013;2013:586076.
2. Manzoni P, Rizzollo S, Decembrino L, et al. Recent advances in prevention of sepsis in the premature neonates in NICU. Early Hum Dev 2011;87:S31-3.
3. Kadambari S, Heath PT, Sharland M, et al. Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units. J Antimicrob Chemother 2011;66:2647-50.
4. Engle WA. Age terminology during the perinatal period. Pediatrics 2004;114:1362-4.
5. Clark RH, Bloom BT, Spitzer AR, et al. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006;117:1979-87.
6. Zingg W, Pfister R, Posfay-Barbe KM, et al. Secular trends in antibiotic use among neonates: 2001-2008. Pediatr Infect Dis J 2011;30:365-70.
7. Zingg W, Posfay-Barbe KM. Antibiotic use in children - off-label use. Curr Drug Targets 2012;13:885-92.
8. Neubert A, Lukas K, Leis T, et al. Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis. Eur J Clin Pharmacol 2010;66:87-95.
9. Edmond K, Zaidi A. New approaches to preventing, diagnosing, and treating neonatal sepsis. PLoS Med 2010;7:e1000213.
10. Lutsar I, Metsvaht T. Understanding pharmacokinetics pharmacodynamics in managing neonatal sepsis. Curr Opin Infect Dis 2010;23:201-7.
11. http://www.eucast.org
12. http://www.clsi.org
13. Asín E, Isla A, Canut A, et al. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria. Int J Antimicrob Agents 2012;40:313-22.
14. Smits A, Annaert P, Allegaert K. Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. Int J Pharm 2013;16:8-13.
15. Guidance for industry: exposure-response relationships - study design, data analysis, and regulatory applications. http://www.fda.gov/downloads/Drugs
16. European Medicines Agency. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. Ref. CPMP/EWP/2655/99). http://www.ema.europa.eu
17. European Medicines Agency. Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev 1). http://www.ema.europa.eu
18. Setiabudy R, Suwento R, Rundjan L, et al. Lack of a relationship between the serum concentration of aminoglycosides and ototoxicity in neonates. Int J Clin Pharmacol Ther 2013;51:401-6.
19. De Cock RFW, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet 2012;51:105-17.
20. Abdel-Hady E, El Hamamsy M, Hedaya M, et al. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. J Clin Pharm Ther 2011;36:45-52.
21. Schreuder MF, Wilhelm AJ, Bökenkamp A, et al. Impact of gestational age and birth weight on amikacin clearance on day 1 of life. Clin J Am Soc Nephrol 2009;4:1774-8.
22. Siddiqi A, Khan DA, Khan FA, et al. Therapeutic drug monitoring of amikacin in preterm and term infants. Singapore Med J 2009;50:486-9.
23. Sherwin CMT, Svahn S, Van der Linden A, et al. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 2009;65:705-13.
24. Allegaert K, Anderson BJ, van den Anker JN, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit 2007;29:284-91.
25. Allegaert K, Cossey V, Debeer A, et al. The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age. Pediatr Nephrol 2005;20:740-3.
26. Tréluyer JM, Merlé Y, Tonnelier S, et al. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother 2002;46:1381-7.
27. Labaune JM, Bleyzac N, Maire P, et al. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. Biol Neonate 2001;80:142-7.
28. Wang J, Liang WQ, Wu JJ, et al. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method. Acta Pharmacol Sin 2000;21:954-60.
29. Langhendries JP, Battisti O, Bertrand JM, et al. Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit. Biol Neonate 1998;74:351-62.
30. Botha JH, du Preez MJ, Miller R, et al. Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models. Eur J Clin Pharmacol 1998;53:337-41.
31. Petersen PO, Wells TG, Kearns GL. Amikacin dosing in neonates: evaluation of a dosing chart based on population pharmacokinetic data. Dev Pharmacol Ther 1991;16:203-11.
32. Kenyon CF, Knoppert DC, Lee SK, et al. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother 1990;34:265-8.
33. Admiraal R, van Kesteren C, Boelens JJ, et al. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Arch Dis Child 2014;99:267-72.
34. Jacqz-Aigrain E, Zhao W, Sharland M, et al. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med 2013;18:28-34.
35. Cohen-Wolkowiez M, Ouellet D, Smith PB, et al. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother 2012;56:1828-37.
36. Suyagh M, Collier PS, Millership JS, et al. Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics 2011;127:e367-374.
37. Pandolfini C1, Kaguelidou F, Sequi M, et al. Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections. Eur J Clin Pharmacol 2013;69:1031-6.
38. NICE Clinical Guidence: Antibiotics for early-onset neonatal infection. 2012.
39. Porta A, Hsia Y, Doerholt K, et al. Comparing neonatal and paediatric antibiotic prescribing between hospitals: a new algorithm to help international benchmarking. J Antimicrob Chemother 2012;67:1278-86.
40. Neofax. Thomson Reuters Clinical Editorial Staff. 2011.
41. RedBook. American Academy of Pediatrics. 2013.
42. Kaguelidou F, Turner MA, Choonara I, et al. Randomized controlled trials of antibiotics for neonatal infections: a systematic review. Br J Clin Pharmacol 2013;76:21-9.
43. Pansieri C, Bonati M, Choonara I, et al. Neonatal drug trials: impact of EU and US paediatric regulations. Arch Dis Child Fetal Neonatal Ed 2014;99:F438.
44. Benjamin DK Jr, Smith PB, Murphy MD, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 2006;296:1266-73.
45. Nicklin S, Spencer SA. Recruitment failure in early neonatal research. Arch Dis Child Fetal Neonatal Ed 2004;89:F281.
46. Amiel P, Moreau D, Vincent-Genod C, et al. Noninvitation of eligible individuals to participate in pediatric studies: a qualitative study. Arch Pediatr Adolesc Med 2007;161:446-50.